BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

769 related articles for article (PubMed ID: 34495700)

  • 1. Cytoplasmic Tail Truncation of SARS-CoV-2 Spike Protein Enhances Titer of Pseudotyped Vectors but Masks the Effect of the D614G Mutation.
    Chen HY; Huang C; Tian L; Huang X; Zhang C; Llewellyn GN; Rogers GL; Andresen K; O'Gorman MRG; Chen YW; Cannon PM
    J Virol; 2021 Oct; 95(22):e0096621. PubMed ID: 34495700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
    Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 Spike Alterations Enhance Pseudoparticle Titers and Replication-Competent VSV-SARS-CoV-2 Virus.
    Havranek KE; Jimenez AR; Acciani MD; Lay Mendoza MF; Reyes Ballista JM; Diaz DA; Brindley MA
    Viruses; 2020 Dec; 12(12):. PubMed ID: 33353101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective screening of SARS-CoV-2 neutralizing antibodies in patient serum using lentivirus particles pseudotyped with SARS-CoV-2 spike glycoprotein.
    Tandon R; Mitra D; Sharma P; McCandless MG; Stray SJ; Bates JT; Marshall GD
    Sci Rep; 2020 Nov; 10(1):19076. PubMed ID: 33154514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of SARS-CoV-2 neutralizing antibodies using a vesicular stomatitis virus possessing SARS-CoV-2 spike protein.
    Tani H; Kimura M; Tan L; Yoshida Y; Ozawa T; Kishi H; Fukushi S; Saijo M; Sano K; Suzuki T; Kawasuji H; Ueno A; Miyajima Y; Fukui Y; Sakamaki I; Yamamoto Y; Morinaga Y
    Virol J; 2021 Jan; 18(1):16. PubMed ID: 33435994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. D614G Substitution of SARS-CoV-2 Spike Protein Increases Syncytium Formation and Virus Titer via Enhanced Furin-Mediated Spike Cleavage.
    Cheng YW; Chao TL; Li CL; Wang SH; Kao HC; Tsai YM; Wang HY; Hsieh CL; Lin YY; Chen PJ; Chang SY; Yeh SH
    mBio; 2021 Aug; 12(4):e0058721. PubMed ID: 34311586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment of replication-competent vesicular stomatitis virus recapitulating SADS-CoV entry.
    Zhu Z; Han Y; Gong M; Sun B; Zhang R; Ding Q
    J Virol; 2024 May; 98(5):e0195723. PubMed ID: 38557247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Robust neutralization assay based on SARS-CoV-2 S-protein-bearing vesicular stomatitis virus (VSV) pseudovirus and ACE2-overexpressing BHK21 cells.
    Xiong HL; Wu YT; Cao JL; Yang R; Liu YX; Ma J; Qiao XY; Yao XY; Zhang BH; Zhang YL; Hou WH; Shi Y; Xu JJ; Zhang L; Wang SJ; Fu BR; Yang T; Ge SX; Zhang J; Yuan Q; Huang BY; Li ZY; Zhang TY; Xia NS
    Emerg Microbes Infect; 2020 Dec; 9(1):2105-2113. PubMed ID: 32893735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimised Method for the Production and Titration of Lentiviral Vectors Pseudotyped with the SARS-CoV-2 Spike.
    Mekkaoui L; Bentley EM; Ferrari M; Lamb K; Ward K; Karattil R; Akbar Z; Bughda R; Sillibourne J; Onuoha S; Mattiuzzo G; Takeuchi Y; Pule M
    Bio Protoc; 2021 Aug; 11(16):e4194. PubMed ID: 34541054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pseudotyped vesicular stomatitis virus for analysis of virus entry mediated by SARS coronavirus spike proteins.
    Fukushi S; Watanabe R; Taguchi F
    Methods Mol Biol; 2008; 454():331-8. PubMed ID: 19057867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A vesicular stomatitis virus-based prime-boost vaccination strategy induces potent and protective neutralizing antibodies against SARS-CoV-2.
    Kim GN; Choi JA; Wu K; Saeedian N; Yang E; Park H; Woo SJ; Lim G; Kim SG; Eo SK; Jeong HW; Kim T; Chang JH; Seo SH; Kim NH; Choi E; Choo S; Lee S; Winterborn A; Li Y; Parham K; Donovan JM; Fenton B; Dikeakos JD; Dekaban GA; Haeryfar SMM; Troyer RM; Arts EJ; Barr SD; Song M; Kang CY
    PLoS Pathog; 2021 Dec; 17(12):e1010092. PubMed ID: 34914812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human Immunodeficiency Viruses Pseudotyped with SARS-CoV-2 Spike Proteins Infect a Broad Spectrum of Human Cell Lines through Multiple Entry Mechanisms.
    Xu C; Wang A; Geng K; Honnen W; Wang X; Bruiners N; Singh S; Ferrara F; D'Angelo S; Bradbury ARM; Gennaro ML; Liu D; Pinter A; Chang TL
    Viruses; 2021 May; 13(6):. PubMed ID: 34064066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spike mutation D614G alters SARS-CoV-2 fitness.
    Plante JA; Liu Y; Liu J; Xia H; Johnson BA; Lokugamage KG; Zhang X; Muruato AE; Zou J; Fontes-Garfias CR; Mirchandani D; Scharton D; Bilello JP; Ku Z; An Z; Kalveram B; Freiberg AN; Menachery VD; Xie X; Plante KS; Weaver SC; Shi PY
    Nature; 2021 Apr; 592(7852):116-121. PubMed ID: 33106671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive and systemic optimization for improving the yield of SARS-CoV-2 spike pseudotyped virus.
    Fu X; Tao L; Zhang X
    Mol Ther Methods Clin Dev; 2021 Mar; 20():350-356. PubMed ID: 33521163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses.
    Schmidt F; Weisblum Y; Muecksch F; Hoffmann HH; Michailidis E; Lorenzi JCC; Mendoza P; Rutkowska M; Bednarski E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Caskey M; Robbiani DF; Nussenzweig MC; Rice CM; Hatziioannou T; Bieniasz PD
    J Exp Med; 2020 Nov; 217(11):. PubMed ID: 32692348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Assessment of Serological Assays for SARS-CoV-2 as Surrogates for Authentic Virus Neutralization.
    Wohlgemuth N; Whitt K; Cherry S; Kirkpatrick Roubidoux E; Lin CY; Allison KJ; Gowen A; Freiden P; Allen EK; ; Gaur AH; Estepp JH; Tang L; Mori T; Hijano DR; Hakim H; McGargill MA; Krammer F; Whitt MA; Wolf J; Thomas PG; Schultz-Cherry S
    Microbiol Spectr; 2021 Oct; 9(2):e0105921. PubMed ID: 34704832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retroviral vectors pseudotyped with severe acute respiratory syndrome coronavirus S protein.
    Giroglou T; Cinatl J; Rabenau H; Drosten C; Schwalbe H; Doerr HW; von Laer D
    J Virol; 2004 Sep; 78(17):9007-15. PubMed ID: 15308697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2.
    Nie J; Li Q; Wu J; Zhao C; Hao H; Liu H; Zhang L; Nie L; Qin H; Wang M; Lu Q; Li X; Sun Q; Liu J; Fan C; Huang W; Xu M; Wang Y
    Emerg Microbes Infect; 2020 Dec; 9(1):680-686. PubMed ID: 32207377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Spike D614G mutation increases SARS-CoV-2 infection of multiple human cell types.
    Daniloski Z; Jordan TX; Ilmain JK; Guo X; Bhabha G; tenOever BR; Sanjana NE
    Elife; 2021 Feb; 10():. PubMed ID: 33570490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncoretrovirus and lentivirus vectors pseudotyped with lymphocytic choriomeningitis virus glycoprotein: generation, concentration, and broad host range.
    Beyer WR; Westphal M; Ostertag W; von Laer D
    J Virol; 2002 Feb; 76(3):1488-95. PubMed ID: 11773421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.